MLB Weekly Digest September 3rd Edition - NGSC Sports
Trachoma Can Cause Irreversible Blindness: Know More
The World Health Organisation (WHO) has set a target for global elimination of trachoma by 2030. Trachoma is a neglected tropical disease that is responsible for blindness or visual impairment in about 1.9 million people globally.A leading cause of blindness worldwide, trachoma is an infectious disease of the eye caused by the bacterium Chlamydia trachomatis. The infection is transmitted from person to person through contact with respiratory discharges (eyes or nose) from an infected person, either through contaminated hands or by flies. Trachoma transmission is commonly associated with poor hygiene, overcrowded households, inadequate access to water or improper sanitation facilities. The World Health Organisation (WHO) has set a target for global elimination of trachoma by 2030.
As of June 2022, trachoma remains a public health problem in 41 countries, with about 125 million people at risk of trachoma blindness, according to the World Health Organisation (WHO). People living in the poorest and most rural areas of Africa, Central and South America, Asia, the Western Pacific and the Middle East are mainly affected by the disease. The WHO African Region accounts for 84 per cent of the global trachoma burden, with 105 million people living in at-risk areas.
Trachoma in WHO's African RegionBenin and Mali recently received WHO validation for trachoma elimination, becoming the fifth and sixth countries in the WHO's African Region to achieve this significant milestone, after Ghana, Gambia, Togo, Malawi. Over the past few years, there has been significant progress in the fight against trachoma in the WHO's African Region. Antibiotic treatment for trachoma was required for 105 million people in the WHO African Region in 2022, as compared to 189 million in 2014, according to WHO report. But trachoma is still endemic in 23 countries in WHO's African Region.
So far, 17 countries have been able to eliminate trachoma as a public health problem. These are Cambodia, China, the Gambia, Ghana, Islamic Republic of Iran, Lao People's Democratic Republic, Malawi, Mexico, Morocco, Myanmar, Nepal, Oman, Saudi Arabia, Togo and Vanuatu, Benin and Mali.
Trachoma symptoms and complicationsTrachoma can cause irreversible blindness. The bacterial infection is the cause of blindness or visual impairment in about 1.9 million people globally, as per WHO.
In 2021, over 69000 people required surgical treatment for advanced stage trachoma while more than 64 million people were treated with antibiotics.
Repeated trachoma infection over many years can cause the inside of the eyelid to become severely scarred and turn inwards, thereby leading the eyelashes to rub against the eyeball. This can cause constant pain and light intolerance and may lead to scarring of the cornea. Left untreated, this condition can result in visual impairment or blindness.
WHO recommends SAFE strategy for Trachoma EliminationThe SAFE strategy recommended by WHO to eliminate trachoma consists of:
S: Surgery to treat late trachoma complications
A: Antibiotics to clear infection
F: Facial cleanliness
E: Environmental improvement, including improved access to water and sanitation to reduce transmission.
The US-based pharmaceutical company Pfizer is donating the antibiotic azithromycin to countries implementing the SAFE strategy, through the International Trachoma Initiative.
Neglected tropical diseases (NTDs)Trachoma is one of the neglected tropical diseases (NTDs) that mostly affect impoverished communities in tropical areas, particularly women and children. These diseases cause devastating health consequences to more than one billion people globally.
Here's the list of neglected tropical diseases (NTDs):
Follow us on
Noma Survivors Shine A Light On Neglected Disease [press Release]
In many ways, Muhammadu, Mulikat and Dahiru have little in common. They were born in different corners of Nigeria (Yobe state in the northeast, Lagos in the southwest and Niger state, in the centre) and grew up in different circumstances and with different dreams. But one day, when they were still children, their lives and those of their relatives changed forever because of noma.
Noma is a completely preventable disease, easy to treat if addressed in time. Untreated, it eats away the skin and bones of the face in just a few weeks, leading to death for up to 90 per cent of people infected, most of whom are children. The 10 per cent who survive are left with a future of pain, discomfort and social stigma.
Today, noma survivors Muhammadu, Mulikat and Dahiru see each other every day at Sokoto Noma Hospital, which is supported by Médecins Sans Frontières (MSF). All three arrived after long journeys seeking help for their condition. After receiving treatment and several rounds of surgery each, they regained confidence and hope for the future. All three decided to stay at the hospital and become part of the solution.
"My father took me to several places in search of a cure, including three months in a hospital in Maiduguri, in the northeast," says Muhammadu, now a secondary school student at a local school and a cleaner at Sokoto Noma Hospital. "Someone told us about a hospital in Sokoto, but it was very far from our town. My father had to sell some animals to pay for the transport."
When Muhammadu arrived in Sokoto, he could barely open his mouth, making eating and talking almost impossible. After two rounds of surgery, his condition and his outlook have improved immeasurably. "I can go anywhere now, and I don't feel ashamed," he says. "In addition, I strive to educate others about noma: so they know, for example, that cleaning their mouths daily reduces the risk."
Muhammadu is following the example of Mulikat, a powerful advocate in the fight against noma. Mulikat is also, without a doubt, the most elegant person in this hospital. Looking impeccable in her colourful dresses, Mulikat works with the health and mental health promotion teams. Telling her story helps people within local communities to recognise the disease early and helps children with noma and their families not to lose hope.
"I understand their suffering well," says Mulikat. "I was crying all the time and I often wished I hadn't survived to witness the stigma and social impact of the disease," she says.
"For a long time, I did not want to socialise. Luckily, they brought me here. In 20 years, I've undergone five rounds of surgery. Now I am fine, and I am fighting for noma to be officially recognised as a neglected tropical disease."
Dahiru pushes a stretcher with a child who has just finished his first round of surgery. He remembers his first surgery very well, soon after he arrived at Sokoto noma hospital as a teenager from Niger state. Recovering in hospital, he met his first wife, Fatima, also a noma survivor, and decided to stay on and work at the hospital as a cleaner and warden. Unfortunately, Fatima died giving birth to twins, who also died. "It was very hard," says Dahiru, "but I remarried and now I have two healthy children. I hope they can go to school soon."
The hospital has become a place of hope for Muhammadu, Dahiru and Mulikat. Not only have they had their dignity restored through the long process of recovering from noma, they have also found the means to live the dreams that had been once snatched from them by the disease: dreams of a normal life, an education, a job, a family. As they perform their daily duties in and around the hospital, they are an inspiration to the people affected by noma and other survivors who arrive at Sokoto often feeling as hopeless as they once did.
Education is very important for all three. They see it as the key to making choices about the future, now that noma no longer holds them back.
Mulikat returned to education and succeeded in gaining a diploma in health information management in 2018. She is also a co-founder of Elysium, noma's first survivors' foundation, while she has travelled abroad to share her story and raise awareness of the disease.
"In 2022, I left Nigeria for the first time, to travel abroad to talk to those who take decisions and ask them to give noma the attention it deserves," she says.
Muhammadu made a decision on arriving at the hospital. "I felt I had to learn to read so that one day I could become a medic," he says. "The doctors supported me to stay in Sokoto and go to a boarding school here and my father accepted. During the holidays I stayed in the hospital, cleaning cars to get some money. And then I got a job as a cleaner here. My plan is still to become a doctor."
I'm happy now. When I see my life before, and now, I feel very happy. I can't believe that now I'm the one helping others. Dahiru, noma survivor and health worker at Sokoto Noma Hospital
Muhammadu and Dahiru are now friends. Although they work at different locations within the hospital, their meetings are filled with warmth as they smile and exchange pleasantries and news.
"I'm happy now," says Dahiru. "When I see my life before, and now, I feel very happy. I can't believe that now I'm the one helping others."
Today, noma is closer than ever to official inclusion on the World Health Organization's list of neglected tropical diseases, which should bring more attention and more resources for tackling it. This year will hopefully be a turning point in the lives of Muhammadu, Mulikat, Dahiru and all the other people suffering from or living with the consequences of noma.
MSF has supported the Nigerian Ministry of Health's Sokoto Noma Hospital since 2014, providing reconstructive surgery, nutritional support, mental health support and outreach activities. Since 2014, MSF's surgical teams have carried out 1,152 surgeries on 801 patients. All services at Sokoto noma hospital are provided free of charge.
Provided by SyndiGate Media Inc. (Syndigate.Info).Global Neglected Tropical Diseases Diagnosis Market To Reach $10.3 Billion By 2030
ReportLinker
The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet.
New York, May 17, 2023 (GLOBE NEWSWIRE) -- Reportlinker.Com announces the release of the report "Global Neglected Tropical Diseases Diagnosis Industry" - https://www.Reportlinker.Com/p06032319/?Utm_source=GNWFood and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.
Global Neglected Tropical Diseases Diagnosis Market to Reach $10.3 Billion by 2030
In the changed post COVID-19 business landscape, the global market for Neglected Tropical Diseases Diagnosis estimated at US$5.5 Billion in the year 2022, is projected to reach a revised size of US$10.3 Billion by 2030, growing at aCAGR of 8% over the period 2022-2030. Conventional, one of the segments analyzed in the report, is projected to record 7.2% CAGR and reach US$5.4 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Molecular / Modern segment is readjusted to a revised 9.1% CAGR for the next 8-year period.
The U.S. Market is Estimated at $1.5 Billion, While China is Forecast to Grow at 11.7% CAGR
The Neglected Tropical Diseases Diagnosis market in the U.S. Is estimated at US$1.5 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.2 Billion by the year 2030 trailing a CAGR of 11.7% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.4% and 6.7% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 6.3% CAGR.
Select Competitors (Total 33 Featured)- Abbott Laboratories- Beckman Coulter/Danaher- Bio-Rad Laboratories, Inc.- Coris Bioconcept SPRL- DiaSys Diagnostic Systems GmbH- F. Hoffmann-La Roche Ltd.- Genome Diagnostics Pvt. Ltd- InBios International, Inc.- Life Technology- Novartis Diagnostics., Ltd.- Omega Diagnostics Group PLC- Ortho-Clinical Diagnostics- Oscar Medicare Pvt Ltd.- Premier Medical Corporation Ltd.- Siemens Healthcare- Thermo Fisher Scientific, Inc.- Wako Chemicals, Inc.- ZeptoMetrix
Read the full report: https://www.Reportlinker.Com/p06032319/?Utm_source=GNW
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEWImpact of Covid-19 and a Looming Global RecessionNeglected Tropical Diseases Diagnosis - Global Key CompetitorsPercentage Market Share in 2022 (E)Competitive Market Presence - Strong/Active/Niche/Trivial forPlayers Worldwide in 2022 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVETable 1: World Recent Past, Current & Future Analysis forNeglected Tropical Diseases Diagnosis by Geographic Region -USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,Middle East and Africa Markets - Independent Analysis of AnnualSales in US$ Million for Years 2022 through 2030 and % CAGR
Table 2: World Historic Review for Neglected Tropical DiseasesDiagnosis by Geographic Region - USA, Canada, Japan, China,Europe, Asia-Pacific, Latin America, Middle East and AfricaMarkets - Independent Analysis of Annual Sales in US$ Millionfor Years 2014 through 2021 and % CAGR
Table 3: World 16-Year Perspective for Neglected TropicalDiseases Diagnosis by Geographic Region - Percentage Breakdownof Value Sales for USA, Canada, Japan, China, Europe,Asia-Pacific, Latin America, Middle East and Africa Markets forYears 2014, 2023 & 2030
Table 4: World Recent Past, Current & Future Analysis forConventional by Geographic Region - USA, Canada, Japan, China,Europe, Asia-Pacific, Latin America, Middle East and AfricaMarkets - Independent Analysis of Annual Sales in US$ Millionfor Years 2022 through 2030 and % CAGR
Table 5: World Historic Review for Conventional by GeographicRegion - USA, Canada, Japan, China, Europe, Asia-Pacific, LatinAmerica, Middle East and Africa Markets - Independent Analysisof Annual Sales in US$ Million for Years 2014 through 2021 and% CAGR
Table 6: World 16-Year Perspective for Conventional byGeographic Region - Percentage Breakdown of Value Sales forUSA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,Middle East and Africa for Years 2014, 2023 & 2030
Table 7: World Recent Past, Current & Future Analysis forMolecular / Modern by Geographic Region - USA, Canada, Japan,China, Europe, Asia-Pacific, Latin America, Middle East andAfrica Markets - Independent Analysis of Annual Sales in US$Million for Years 2022 through 2030 and % CAGR
Table 8: World Historic Review for Molecular / Modern byGeographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific, Latin America, Middle East and Africa Markets -Independent Analysis of Annual Sales in US$ Million for Years2014 through 2021 and % CAGR
Table 9: World 16-Year Perspective for Molecular / Modern byGeographic Region - Percentage Breakdown of Value Sales forUSA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,Middle East and Africa for Years 2014, 2023 & 2030
Table 10: World Recent Past, Current & Future Analysis forCentralized by Geographic Region - USA, Canada, Japan, China,Europe, Asia-Pacific, Latin America, Middle East and AfricaMarkets - Independent Analysis of Annual Sales in US$ Millionfor Years 2022 through 2030 and % CAGR
Table 11: World Historic Review for Centralized by GeographicRegion - USA, Canada, Japan, China, Europe, Asia-Pacific, LatinAmerica, Middle East and Africa Markets - Independent Analysisof Annual Sales in US$ Million for Years 2014 through 2021 and% CAGR
Table 12: World 16-Year Perspective for Centralized byGeographic Region - Percentage Breakdown of Value Sales forUSA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,Middle East and Africa for Years 2014, 2023 & 2030
Table 13: World Recent Past, Current & Future Analysis forPoint of Care by Geographic Region - USA, Canada, Japan, China,Europe, Asia-Pacific, Latin America, Middle East and AfricaMarkets - Independent Analysis of Annual Sales in US$ Millionfor Years 2022 through 2030 and % CAGR
Table 14: World Historic Review for Point of Care by GeographicRegion - USA, Canada, Japan, China, Europe, Asia-Pacific, LatinAmerica, Middle East and Africa Markets - Independent Analysisof Annual Sales in US$ Million for Years 2014 through 2021 and% CAGR
Table 15: World 16-Year Perspective for Point of Care byGeographic Region - Percentage Breakdown of Value Sales forUSA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,Middle East and Africa for Years 2014, 2023 & 2030
Table 16: World Recent Past, Current & Future Analysis forClinical Labs by Geographic Region - USA, Canada, Japan, China,Europe, Asia-Pacific, Latin America, Middle East and AfricaMarkets - Independent Analysis of Annual Sales in US$ Millionfor Years 2022 through 2030 and % CAGR
Table 17: World Historic Review for Clinical Labs by GeographicRegion - USA, Canada, Japan, China, Europe, Asia-Pacific, LatinAmerica, Middle East and Africa Markets - Independent Analysisof Annual Sales in US$ Million for Years 2014 through 2021 and% CAGR
Table 18: World 16-Year Perspective for Clinical Labs byGeographic Region - Percentage Breakdown of Value Sales forUSA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,Middle East and Africa for Years 2014, 2023 & 2030
Table 19: World Recent Past, Current & Future Analysis forHospitals & Clinics by Geographic Region - USA, Canada, Japan,China, Europe, Asia-Pacific, Latin America, Middle East andAfrica Markets - Independent Analysis of Annual Sales in US$Million for Years 2022 through 2030 and % CAGR
Table 20: World Historic Review for Hospitals & Clinics byGeographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific, Latin America, Middle East and Africa Markets -Independent Analysis of Annual Sales in US$ Million for Years2014 through 2021 and % CAGR
Table 21: World 16-Year Perspective for Hospitals & Clinics byGeographic Region - Percentage Breakdown of Value Sales forUSA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,Middle East and Africa for Years 2014, 2023 & 2030
Table 22: World Recent Past, Current & Future Analysis for HomeHealthcare by Geographic Region - USA, Canada, Japan, China,Europe, Asia-Pacific, Latin America, Middle East and AfricaMarkets - Independent Analysis of Annual Sales in US$ Millionfor Years 2022 through 2030 and % CAGR
Table 23: World Historic Review for Home Healthcare byGeographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific, Latin America, Middle East and Africa Markets -Independent Analysis of Annual Sales in US$ Million for Years2014 through 2021 and % CAGR
Table 24: World 16-Year Perspective for Home Healthcare byGeographic Region - Percentage Breakdown of Value Sales forUSA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,Middle East and Africa for Years 2014, 2023 & 2030
Table 25: World Neglected Tropical Diseases Diagnosis MarketAnalysis of Annual Sales in US$ Million for Years 2014 through2030
III. MARKET ANALYSIS
UNITED STATESNeglected Tropical Diseases Diagnosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Statesfor 2023 (E)Table 26: USA Recent Past, Current & Future Analysis forNeglected Tropical Diseases Diagnosis by Method - Conventionaland Molecular / Modern - Independent Analysis of Annual Salesin US$ Million for the Years 2022 through 2030 and % CAGR
Table 27: USA Historic Review for Neglected Tropical DiseasesDiagnosis by Method - Conventional and Molecular / ModernMarkets - Independent Analysis of Annual Sales in US$ Millionfor Years 2014 through 2021 and % CAGR
Table 28: USA 16-Year Perspective for Neglected TropicalDiseases Diagnosis by Method - Percentage Breakdown of ValueSales for Conventional and Molecular / Modern for the Years2014, 2023 & 2030
Table 29: USA Recent Past, Current & Future Analysis forNeglected Tropical Diseases Diagnosis by Service Type -Centralized and Point of Care - Independent Analysis of AnnualSales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 30: USA Historic Review for Neglected Tropical DiseasesDiagnosis by Service Type - Centralized and Point of CareMarkets - Independent Analysis of Annual Sales in US$ Millionfor Years 2014 through 2021 and % CAGR
Table 31: USA 16-Year Perspective for Neglected TropicalDiseases Diagnosis by Service Type - Percentage Breakdown ofValue Sales for Centralized and Point of Care for the Years2014, 2023 & 2030
Table 32: USA Recent Past, Current & Future Analysis forNeglected Tropical Diseases Diagnosis by End-Use - ClinicalLabs, Hospitals & Clinics and Home Healthcare - IndependentAnalysis of Annual Sales in US$ Million for the Years 2022through 2030 and % CAGR
Table 33: USA Historic Review for Neglected Tropical DiseasesDiagnosis by End-Use - Clinical Labs, Hospitals & Clinics andHome Healthcare Markets - Independent Analysis of Annual Salesin US$ Million for Years 2014 through 2021 and % CAGR
Table 34: USA 16-Year Perspective for Neglected TropicalDiseases Diagnosis by End-Use - Percentage Breakdown of ValueSales for Clinical Labs, Hospitals & Clinics and HomeHealthcare for the Years 2014, 2023 & 2030
CANADATable 35: Canada Recent Past, Current & Future Analysis forNeglected Tropical Diseases Diagnosis by Method - Conventionaland Molecular / Modern - Independent Analysis of Annual Salesin US$ Million for the Years 2022 through 2030 and % CAGR
Table 36: Canada Historic Review for Neglected TropicalDiseases Diagnosis by Method - Conventional and Molecular /Modern Markets - Independent Analysis of Annual Sales in US$Million for Years 2014 through 2021 and % CAGR
Table 37: Canada 16-Year Perspective for Neglected TropicalDiseases Diagnosis by Method - Percentage Breakdown of ValueSales for Conventional and Molecular / Modern for the Years2014, 2023 & 2030
Table 38: Canada Recent Past, Current & Future Analysis forNeglected Tropical Diseases Diagnosis by Service Type -Centralized and Point of Care - Independent Analysis of AnnualSales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 39: Canada Historic Review for Neglected TropicalDiseases Diagnosis by Service Type - Centralized and Point ofCare Markets - Independent Analysis of Annual Sales in US$Million for Years 2014 through 2021 and % CAGR
Table 40: Canada 16-Year Perspective for Neglected TropicalDiseases Diagnosis by Service Type - Percentage Breakdown ofValue Sales for Centralized and Point of Care for the Years2014, 2023 & 2030
Table 41: Canada Recent Past, Current & Future Analysis forNeglected Tropical Diseases Diagnosis by End-Use - ClinicalLabs, Hospitals & Clinics and Home Healthcare - IndependentAnalysis of Annual Sales in US$ Million for the Years 2022through 2030 and % CAGR
Table 42: Canada Historic Review for Neglected TropicalDiseases Diagnosis by End-Use - Clinical Labs, Hospitals &Clinics and Home Healthcare Markets - Independent Analysis ofAnnual Sales in US$ Million for Years 2014 through 2021 and %CAGR
Table 43: Canada 16-Year Perspective for Neglected TropicalDiseases Diagnosis by End-Use - Percentage Breakdown of ValueSales for Clinical Labs, Hospitals & Clinics and HomeHealthcare for the Years 2014, 2023 & 2030
JAPANNeglected Tropical Diseases Diagnosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)Table 44: Japan Recent Past, Current & Future Analysis forNeglected Tropical Diseases Diagnosis by Method - Conventionaland Molecular / Modern - Independent Analysis of Annual Salesin US$ Million for the Years 2022 through 2030 and % CAGR
Table 45: Japan Historic Review for Neglected Tropical DiseasesDiagnosis by Method - Conventional and Molecular / ModernMarkets - Independent Analysis of Annual Sales in US$ Millionfor Years 2014 through 2021 and % CAGR
Table 46: Japan 16-Year Perspective for Neglected TropicalDiseases Diagnosis by Method - Percentage Breakdown of ValueSales for Conventional and Molecular / Modern for the Years2014, 2023 & 2030
Table 47: Japan Recent Past, Current & Future Analysis forNeglected Tropical Diseases Diagnosis by Service Type -Centralized and Point of Care - Independent Analysis of AnnualSales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 48: Japan Historic Review for Neglected Tropical DiseasesDiagnosis by Service Type - Centralized and Point of CareMarkets - Independent Analysis of Annual Sales in US$ Millionfor Years 2014 through 2021 and % CAGR
Table 49: Japan 16-Year Perspective for Neglected TropicalDiseases Diagnosis by Service Type - Percentage Breakdown ofValue Sales for Centralized and Point of Care for the Years2014, 2023 & 2030
Table 50: Japan Recent Past, Current & Future Analysis forNeglected Tropical Diseases Diagnosis by End-Use - ClinicalLabs, Hospitals & Clinics and Home Healthcare - IndependentAnalysis of Annual Sales in US$ Million for the Years 2022through 2030 and % CAGR
Table 51: Japan Historic Review for Neglected Tropical DiseasesDiagnosis by End-Use - Clinical Labs, Hospitals & Clinics andHome Healthcare Markets - Independent Analysis of Annual Salesin US$ Million for Years 2014 through 2021 and % CAGR
Table 52: Japan 16-Year Perspective for Neglected TropicalDiseases Diagnosis by End-Use - Percentage Breakdown of ValueSales for Clinical Labs, Hospitals & Clinics and HomeHealthcare for the Years 2014, 2023 & 2030
CHINANeglected Tropical Diseases Diagnosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)Table 53: China Recent Past, Current & Future Analysis forNeglected Tropical Diseases Diagnosis by Method - Conventionaland Molecular / Modern - Independent Analysis of Annual Salesin US$ Million for the Years 2022 through 2030 and % CAGR
Table 54: China Historic Review for Neglected Tropical DiseasesDiagnosis by Method - Conventional and Molecular / ModernMarkets - Independent Analysis of Annual Sales in US$ Millionfor Years 2014 through 2021 and % CAGR
Table 55: China 16-Year Perspective for Neglected TropicalDiseases Diagnosis by Method - Percentage Breakdown of ValueSales for Conventional and Molecular / Modern for the Years2014, 2023 & 2030
Table 56: China Recent Past, Current & Future Analysis forNeglected Tropical Diseases Diagnosis by Service Type -Centralized and Point of Care - Independent Analysis of AnnualSales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 57: China Historic Review for Neglected Tropical DiseasesDiagnosis by Service Type - Centralized and Point of CareMarkets - Independent Analysis of Annual Sales in US$ Millionfor Years 2014 through 2021 and % CAGR
Table 58: China 16-Year Perspective for Neglected TropicalDiseases Diagnosis by Service Type - Percentage Breakdown ofValue Sales for Centralized and Point of Care for the Years2014, 2023 & 2030
Table 59: China Recent Past, Current & Future Analysis forNeglected Tropical Diseases Diagnosis by End-Use - ClinicalLabs, Hospitals & Clinics and Home Healthcare - IndependentAnalysis of Annual Sales in US$ Million for the Years 2022through 2030 and % CAGR
Table 60: China Historic Review for Neglected Tropical DiseasesDiagnosis by End-Use - Clinical Labs, Hospitals & Clinics andHome Healthcare Markets - Independent Analysis of Annual Salesin US$ Million for Years 2014 through 2021 and % CAGR
Table 61: China 16-Year Perspective for Neglected TropicalDiseases Diagnosis by End-Use - Percentage Breakdown of ValueSales for Clinical Labs, Hospitals & Clinics and HomeHealthcare for the Years 2014, 2023 & 2030
EUROPENeglected Tropical Diseases Diagnosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)Table 62: Europe Recent Past, Current & Future Analysis forNeglected Tropical Diseases Diagnosis by Geographic Region -France, Germany, Italy, UK, Spain, Russia and Rest of EuropeMarkets - Independent Analysis of Annual Sales in US$ Millionfor Years 2022 through 2030 and % CAGR
Table 63: Europe Historic Review for Neglected TropicalDiseases Diagnosis by Geographic Region - France, Germany,Italy, UK, Spain, Russia and Rest of Europe Markets -Independent Analysis of Annual Sales in US$ Million for Years2014 through 2021 and % CAGR
Table 64: Europe 16-Year Perspective for Neglected TropicalDiseases Diagnosis by Geographic Region - Percentage Breakdownof Value Sales for France, Germany, Italy, UK, Spain, Russiaand Rest of Europe Markets for Years 2014, 2023 & 2030
Table 65: Europe Recent Past, Current & Future Analysis forNeglected Tropical Diseases Diagnosis by Method - Conventionaland Molecular / Modern - Independent Analysis of Annual Salesin US$ Million for the Years 2022 through 2030 and % CAGR
Table 66: Europe Historic Review for Neglected TropicalDiseases Diagnosis by Method - Conventional and Molecular /Modern Markets - Independent Analysis of Annual Sales in US$Million for Years 2014 through 2021 and % CAGR
Table 67: Europe 16-Year Perspective for Neglected TropicalDiseases Diagnosis by Method - Percentage Breakdown of ValueSales for Conventional and Molecular / Modern for the Years2014, 2023 & 2030
Table 68: Europe Recent Past, Current & Future Analysis forNeglected Tropical Diseases Diagnosis by Service Type -Centralized and Point of Care - Independent Analysis of AnnualSales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 69: Europe Historic Review for Neglected TropicalDiseases Diagnosis by Service Type - Centralized and Point ofCare Markets - Independent Analysis of Annual Sales in US$Million for Years 2014 through 2021 and % CAGR
Table 70: Europe 16-Year Perspective for Neglected TropicalDiseases Diagnosis by Service Type - Percentage Breakdown ofValue Sales for Centralized and Point of Care for the Years2014, 2023 & 2030
Table 71: Europe Recent Past, Current & Future Analysis forNeglected Tropical Diseases Diagnosis by End-Use - ClinicalLabs, Hospitals & Clinics and Home Healthcare - IndependentAnalysis of Annual Sales in US$ Million for the Years 2022through 2030 and % CAGR
Table 72: Europe Historic Review for Neglected TropicalDiseases Diagnosis by End-Use - Clinical Labs, Hospitals &Clinics and Home Healthcare Markets - Independent Analysis ofAnnual Sales in US$ Million for Years 2014 through 2021 and %CAGR
Table 73: Europe 16-Year Perspective for Neglected TropicalDiseases Diagnosis by End-Use - Percentage Breakdown of ValueSales for Clinical Labs, Hospitals & Clinics and HomeHealthcare for the Years 2014, 2023 & 2030
FRANCENeglected Tropical Diseases Diagnosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)Table 74: France Recent Past, Current & Future Analysis forNeglected Tropical Diseases Diagnosis by Method - Conventionaland Molecular / Modern - Independent Analysis of Annual Salesin US$ Million for the Years 2022 through 2030 and % CAGR
Table 75: France Historic Review for Neglected TropicalDiseases Diagnosis by Method - Conventional and Molecular /Modern Markets - Independent Analysis of Annual Sales in US$Million for Years 2014 through 2021 and % CAGR
Table 76: France 16-Year Perspective for Neglected TropicalDiseases Diagnosis by Method - Percentage Breakdown of ValueSales for Conventional and Molecular / Modern for the Years2014, 2023 & 2030
Table 77: France Recent Past, Current & Future Analysis forNeglected Tropical Diseases Diagnosis by Service Type -Centralized and Point of Care - Independent Analysis of AnnualSales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 78: France Historic Review for Neglected TropicalDiseases Diagnosis by Service Type - Centralized and Point ofCare Markets - Independent Analysis of Annual Sales in US$Million for Years 2014 through 2021 and % CAGR
Table 79: France 16-Year Perspective for Neglected TropicalDiseases Diagnosis by Service Type - Percentage Breakdown ofValue Sales for Centralized and Point of Care for the Years2014, 2023 & 2030
Table 80: France Recent Past, Current & Future Analysis forNeglected Tropical Diseases Diagnosis by End-Use - ClinicalLabs, Hospitals & Clinics and Home Healthcare - IndependentAnalysis of Annual Sales in US$ Million for the Years 2022through 2030 and % CAGR
Table 81: France Historic Review for Neglected TropicalDiseases Diagnosis by End-Use - Clinical Labs, Hospitals &Clinics and Home Healthcare Markets - Independent Analysis ofAnnual Sales in US$ Million for Years 2014 through 2021 and %CAGR
Table 82: France 16-Year Perspective for Neglected TropicalDiseases Diagnosis by End-Use - Percentage Breakdown of ValueSales for Clinical Labs, Hospitals & Clinics and HomeHealthcare for the Years 2014, 2023 & 2030
GERMANYNeglected Tropical Diseases Diagnosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023(E)Table 83: Germany Recent Past, Current & Future Analysis forNeglected Tropical Diseases Diagnosis by Method - Conventionaland Molecular / Modern - Independent Analysis of Annual Salesin US$ Million for the Years 2022 through 2030 and % CAGR
Table 84: Germany Historic Review for Neglected TropicalDiseases Diagnosis by Method - Conventional and Molecular /Modern Markets - Independent Analysis of Annual Sales in US$Million for Years 2014 through 2021 and % CAGR
Table 85: Germany 16-Year Perspective for Neglected TropicalDiseases Diagnosis by Method - Percentage Breakdown of ValueSales for Conventional and Molecular / Modern for the Years2014, 2023 & 2030
Table 86: Germany Recent Past, Current & Future Analysis forNeglected Tropical Diseases Diagnosis by Service Type -Centralized and Point of Care - Independent Analysis of AnnualSales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 87: Germany Historic Review for Neglected TropicalDiseases Diagnosis by Service Type - Centralized and Point ofCare Markets - Independent Analysis of Annual Sales in US$Million for Years 2014 through 2021 and % CAGR
Table 88: Germany 16-Year Perspective for Neglected TropicalDiseases Diagnosis by Service Type - Percentage Breakdown ofValue Sales for Centralized and Point of Care for the Years2014, 2023 & 2030
Table 89: Germany Recent Past, Current & Future Analysis forNeglected Tropical Diseases Diagnosis by End-Use - ClinicalLabs, Hospitals & Clinics and Home Healthcare - IndependentAnalysis of Annual Sales in US$ Million for the Years 2022through 2030 and % CAGR
Table 90: Germany Historic Review for Neglected TropicalDiseases Diagnosis by End-Use - Clinical Labs, Hospitals &Clinics and Home Healthcare Markets - Independent Analysis ofAnnual Sales in US$ Million for Years 2014 through 2021 and %CAGR
Table 91: Germany 16-Year Perspective for Neglected TropicalDiseases Diagnosis by End-Use - Percentage Breakdown of ValueSales for Clinical Labs, Hospitals & Clinics and HomeHealthcare for the Years 2014, 2023 & 2030
ITALYTable 92: Italy Recent Past, Current & Future Analysis forNeglected Tropical Diseases Diagnosis by Method - Conventionaland Molecular / Modern - Independent Analysis of Annual Salesin US$ Million for the Years 2022 through 2030 and % CAGR
Table 93: Italy Historic Review for Neglected Tropical DiseasesDiagnosis by Method - Conventional and Molecular / ModernMarkets - Independent Analysis of Annual Sales in US$ Millionfor Years 2014 through 2021 and % CAGR
Table 94: Italy 16-Year Perspective for Neglected TropicalDiseases Diagnosis by Method - Percentage Breakdown of ValueSales for Conventional and Molecular / Modern for the Years2014, 2023 & 2030
Table 95: Italy Recent Past, Current & Future Analysis forNeglected Tropical Diseases Diagnosis by Service Type -Centralized and Point of Care - Independent Analysis of AnnualSales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 96: Italy Historic Review for Neglected Tropical DiseasesDiagnosis by Service Type - Centralized and Point of CareMarkets - Independent Analysis of Annual Sales in US$ Millionfor Years 2014 through 2021 and % CAGR
Table 97: Italy 16-Year Perspective for Neglected TropicalDiseases Diagnosis by Service Type - Percentage Breakdown ofValue Sales for Centralized and Point of Care for the Years2014, 2023 & 2030
Table 98: Italy Recent Past, Current & Future Analysis forNeglected Tropical Diseases Diagnosis by End-Use - ClinicalLabs, Hospitals & Clinics and Home Healthcare - IndependentAnalysis of Annual Sales in US$ Million for the Years 2022through 2030 and % CAGR
Table 99: Italy Historic Review for Neglected Tropical DiseasesDiagnosis by End-Use - Clinical Labs, Hospitals & Clinics andHome Healthcare Markets - Independent Analysis of Annual Salesin US$ Million for Years 2014 through 2021 and % CAGR
Table 100: Italy 16-Year Perspective for Neglected TropicalDiseases Diagnosis by End-Use - Percentage Breakdown of ValueSales for Clinical Labs, Hospitals & Clinics and HomeHealthcare for the Years 2014, 2023 & 2030
UNITED KINGDOMNeglected Tropical Diseases Diagnosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdomfor 2023 (E)Table 101: UK Recent Past, Current & Future Analysis forNeglected Tropical Diseases Diagnosis by Method - Conventionaland Molecular / Modern - Independent Analysis of Annual Salesin US$ Million for the Years 2022 through 2030 and % CAGR
Table 102: UK Historic Review for Neglected Tropical DiseasesDiagnosis by Method - Conventional and Molecular / ModernMarkets - Independent Analysis of Annual Sales in US$ Millionfor Years 2014 through 2021 and % CAGR
Table 103: UK 16-Year Perspective for Neglected TropicalDiseases Diagnosis by Method - Percentage Breakdown of ValueSales for Conventional and Molecular / Modern for the Years2014, 2023 & 2030
Table 104: UK Recent Past, Current & Future Analysis forNeglected Tropical Diseases Diagnosis by Service Type -Centralized and Point of Care - Independent Analysis of AnnualSales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 105: UK Historic Review for Neglected Tropical DiseasesDiagnosis by Service Type - Centralized and Point of CareMarkets - Independent Analysis of Annual Sales in US$ Millionfor Years 2014 through 2021 and % CAGR
Table 106: UK 16-Year Perspective for Neglected TropicalDiseases Diagnosis by Service Type - Percentage Breakdown ofValue Sales for Centralized and Point of Care for the Years2014, 2023 & 2030
Table 107: UK Recent Past, Current & Future Analysis forNeglected Tropical Diseases Diagnosis by End-Use - ClinicalLabs, Hospitals & Clinics and Home Healthcare - IndependentAnalysis of Annual Sales in US$ Million for the Years 2022through 2030 and % CAGR
Table 108: UK Historic Review for Neglected Tropical DiseasesDiagnosis by End-Use - Clinical Labs, Hospitals & Clinics andHome Healthcare Markets - Independent Analysis of Annual Salesin US$ Million for Years 2014 through 2021 and % CAGR
Table 109: UK 16-Year Perspective for Neglected TropicalDiseases Diagnosis by End-Use - Percentage Breakdown of ValueSales for Clinical Labs, Hospitals & Clinics and HomeHealthcare for the Years 2014, 2023 & 2030
SPAINTable 110: Spain Recent Past, Current & Future Analysis forNeglected Tropical Diseases Diagnosis by Method - Conventionaland Molecular / Modern - Independent Analysis of Annual Salesin US$ Million for the Years 2022 through 2030 and % CAGR
Table 111: Spain Historic Review for Neglected TropicalDiseases Diagnosis by Method - Conventional and Molecular /Modern Markets - Independent Analysis of Annual Sales in US$Million for Years 2014 through 2021 and % CAGR
Table 112: Spain 16-Year Perspective for Neglected TropicalDiseases Diagnosis by Method - Percentage Breakdown of ValueSales for Conventional and Molecular / Modern for the Years2014, 2023 & 2030
Table 113: Spain Recent Past, Current & Future Analysis forNeglected Tropical Diseases Diagnosis by Service Type -Centralized and Point of Care - Independent Analysis of AnnualSales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 114: Spain Historic Review for Neglected TropicalDiseases Diagnosis by Service Type - Centralized and Point ofCare Markets - Independent Analysis of Annual Sales in US$Million for Years 2014 through 2021 and % CAGR
Table 115: Spain 16-Year Perspective for Neglected TropicalDiseases Diagnosis by Service Type - Percentage Breakdown ofValue Sales for Centralized and Point of Care for the Years2014, 2023 & 2030
Table 116: Spain Recent Past, Current & Future Analysis forNeglected Tropical Diseases Diagnosis by End-Use - ClinicalLabs, Hospitals & Clinics and Home Healthcare - IndependentAnalysis of Annual Sales in US$ Million for the Years 2022through 2030 and % CAGR
Table 117: Spain Historic Review for Neglected TropicalDiseases Diagnosis by End-Use - Clinical Labs, Hospitals &Clinics and Home Healthcare Markets - Independent Analysis ofAnnual Sales in US$ Million for Years 2014 through 2021 and %CAGR
Table 118: Spain 16-Year Perspective for Neglected TropicalDiseases Diagnosis by End-Use - Percentage Breakdown of ValueSales for Clinical Labs, Hospitals & Clinics and HomeHealthcare for the Years 2014, 2023 & 2030
RUSSIATable 119: Russia Recent Past, Current & Future Analysis forNeglected Tropical Diseases Diagnosis by Method - Conventionaland Molecular / Modern - Independent Analysis of Annual Salesin US$ Million for the Years 2022 through 2030 and % CAGR
Table 120: Russia Historic Review for Neglected TropicalDiseases Diagnosis by Method - Conventional and Molecular /Modern Markets - Independent Analysis of Annual Sales in US$Million for Years 2014 through 2021 and % CAGR
Table 121: Russia 16-Year Perspective for Neglected TropicalDiseases Diagnosis by Method - Percentage Breakdown of ValueSales for Conventional and Molecular / Modern for the Years2014, 2023 & 2030
Table 122: Russia Recent Past, Current & Future Analysis forNeglected Tropical Diseases Diagnosis by Service Type -Centralized and Point of Care - Independent Analysis of AnnualSales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 123: Russia Historic Review for Neglected TropicalDiseases Diagnosis by Service Type - Centralized and Point ofCare Markets - Independent Analysis of Annual Sales in US$Million for Years 2014 through 2021 and % CAGR
Table 124: Russia 16-Year Perspective for Neglected TropicalDiseases Diagnosis by Service Type - Percentage Breakdown ofValue Sales for Centralized and Point of Care for the Years2014, 2023 & 2030
Table 125: Russia Recent Past, Current & Future Analysis forNeglected Tropical Diseases Diagnosis by End-Use - ClinicalLabs, Hospitals & Clinics and Home Healthcare - IndependentAnalysis of Annual Sales in US$ Million for the Years 2022through 2030 and % CAGR
Table 126: Russia Historic Review for Neglected TropicalDiseases Diagnosis by End-Use - Clinical Labs, Hospitals &Clinics and Home Healthcare Markets - Independent Analysis ofAnnual Sales in US$ Million for Years 2014 through 2021 and %CAGR
Table 127: Russia 16-Year Perspective for Neglected TropicalDiseases Diagnosis by End-Use - Percentage Breakdown of ValueSales for Clinical Labs, Hospitals & Clinics and HomeHealthcare for the Years 2014, 2023 & 2030
REST OF EUROPETable 128: Rest of Europe Recent Past, Current & FutureAnalysis for Neglected Tropical Diseases Diagnosis by Method -Conventional and Molecular / Modern - Independent Analysis of
Please contact our Customer Support Center to get the complete Table of ContentsRead the full report: https://www.Reportlinker.Com/p06032319/?Utm_source=GNW
About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
Story continues
CONTACT: Clare: clare@reportlinker.Com US: (339)-368-6001 Intl: +1 339-368-6001
Comments
Post a Comment